Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

This study has been terminated.
(Termination of the clinical development program by the Sponsor)
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: January 29, 2010
Last updated: August 8, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 26, 2016